
NTRK TESTING
TEST ALL ADVANCED, METASTATIC SOLID TUMOR PATIENTS FOR NTRKa GENE FUSIONS
Comprehensive testing for all actionable biomarkers, including NTRK gene fusions, can better inform therapy choice
- NCCNa Clinical Practice Guidelines (NCCN Guidelines®) recommend genomic testing in a wide range of tumor types to inform the choice of biomarker-driven therapies1
- 80% to 90% of cancer patients have actionable driver alterations2
NGSa TESTING IS A PREFERRED CHOICE FOR IDENTIFYING NTRK GENE FUSIONS3

NGS testing allows for efficient multiplex testing, with the ability to find NTRK gene fusions, as well as other genomic targets, such as ALK,a BRAF,a EGFR,a and HER2.4-6,a
ASCOa and NCCN guidelines recommend testing for NTRK gene fusions to identify patients with TRK* fusion cancer.3
Select patients for treatment with VITRAKVI® (larotrectinib) based on the presence of an NTRK gene fusion in tumor specimens, as determined by an FDAa-approved test. Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics.7
Contact your pathologist or laboratory to order testing for NTRK gene fusions and TRK fusions proteins.

For more information about testing, click here and connect with one of our Diagnostic Account Managers.
*TRK, tropomyosin receptor kinase.
aALK, anaplastic lymphoma kinase; ASCO, American Society of Clinical Oncology; BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; NCCN, National Comprehensive Cancer Network® (NCCN®); NGS, next-generation sequencing; NTRK, neurotrophic receptor tyrosine kinase.
References
- Korngiebel DM, Zech JM, Chapple A, et al. Practice implications of expanded genetic testing in oncology. Cancer Invest. 2019;37(1):39-45. Return to content
- Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not? ASCO Educational Book. 2017. American Society of Clinical Oncology. Return to content
- Yoshino T, Pentheroudakis G, Mishima S, et al. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020;31(7):861-872. Return to content
- Park HS, Park S-J, Kim JY, et al. Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic resuIts. Ann Surg Treat Res. 2017;92(5):331-339. Return to content
- Fox AJ, Hiemenz MC, Lieberman DB, et al. Next generation sequencing for the detection of actionable mutations in solid and liquid tumors. J Vis Exp. 2016;115:e52758. Return to content
- Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget 2015;6(24):20099-20110. Return to content
- VITRAKVI [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2023. Return to content